Aldehyde dehydrogenase type 2 activation by adenosine and histamine inhibits ischemic norepinephrine release in cardiac sympathetic neurons: mediation by protein kinase Cε

• Published in: The Journal of pharmacology and experimental therapeutics 2012-10, Vol.343 (1), p.97-105
• Main Authors: Robador, Pablo A, Seyedi, Nahid, Chan, Noel Yan-Ki, Koda, Kenichiro, Levi, Roberto
• Format: Article
• Language: English
• Subjects: Aldehyde Dehydrogenase - metabolism; Aldehyde Dehydrogenase, Mitochondrial; Animals; Cardiovascular; Enzyme Activation - drug effects; Enzyme Activation - physiology; Guinea Pigs; Hypoxia - metabolism; Mitochondrial Proteins - metabolism; Myocardial Ischemia - metabolism; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - secretion; Norepinephrine - antagonists & inhibitors; Norepinephrine - secretion; PC12 Cells; Protein Kinase C-epsilon - physiology; Rats; Receptors, Histamine - metabolism; Receptors, Purinergic P1 - metabolism; Sympathetic Fibers, Postganglionic - drug effects; Sympathetic Fibers, Postganglionic - metabolism; Sympathetic Fibers, Postganglionic - secretion; Synaptosomes - drug effects; Synaptosomes - metabolism; Synaptosomes - secretion
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.112.196626

During myocardial ischemia/reperfusion, lipid peroxidation leads to the formation of toxic aldehydes that contribute to ischemic dysfunction. Mitochondrial aldehyde dehydrogenase type 2 (ALDH2) alleviates ischemic heart damage and reperfusion arrhythmias via aldehyde detoxification. Because excessive norepinephrine release in the heart is a pivotal arrhythmogenic mechanism, we hypothesized that neuronal ALDH2 activation might diminish ischemic norepinephrine release. Incubation of cardiac sympathetic nerve endings with acetaldehyde, at concentrations achieved in myocardial ischemia, caused a concentration-dependent increase in norepinephrine release. A major increase in norepinephrine release also occurred when sympathetic nerve endings were incubated in hypoxic conditions. ALDH2 activation substantially reduced acetaldehyde- and hypoxia-induced norepinephrine release, an action prevented by inhibition of ALDH2 or protein kinase Cε (PKCε). Selective activation of G(i/o)-coupled adenosine A(1), A(3), or histamine H(3) receptors markedly inhibited both acetaldehyde- and hypoxia-induced norepinephrine release. These effects were also abolished by PKCε and/or ALDH2 inhibition. Moreover, A(1)-, A(3)-, or H(3)-receptor activation increased ALDH2 activity in a sympathetic neuron model (differentiated PC12 cells stably transfected with H(3) receptors). This action was prevented by the inhibition of PKCε and ALDH2. Our findings suggest the existence in sympathetic neurons of a protective pathway initiated by A(1)-, A(3)-, and H(3)-receptor activation by adenosine and histamine released in close proximity of these terminals. This pathway comprises the sequential activation of PKCε and ALDH2, culminating in aldehyde detoxification and inhibition of hypoxic norepinephrine release. Thus, pharmacological activation of PKCε and ALDH2 in cardiac sympathetic nerves may have significant protective effects by alleviating norepinephrine-induced life-threatening arrhythmias that characterize myocardial ischemia/reperfusion.